Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Abrams

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 9, 2006
Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeletonAviva Levine Fridman, Lin Tang, Olga I Kulaeva, et al.
Translational Oncology|October 2, 2010
Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumorsGilda Gali Hillman, Vinita Singh-Gupta, Areen K Al-Bashir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2012
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trialMuneer H Abidi, Rishi Agarwal, Lois Ayash, et al.
Preventive Medicine Reports|July 14, 2023
The impact of high intensity interval training in a diverse group of cancer survivors: CAPABLE, a pilot studyJennifer L Beebe-Dimmer, David G Finlay, Julie J Ruterbusch, et al.
International Journal of Cancer|March 16, 2012
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNAMarie P Piechocki, Gen Sheng Wu, Richard F Jones, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 18, 2013
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaDivaya Bhutani, Jeffrey Zonder, Jason Valent, et al.
Neoplasia (New York, N.Y.)|September 3, 2009
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumorsGilda G Hillman, Vinita Singh-Gupta, Hao Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|July 23, 2003
Responsiveness of experimental prostate carcinoma bone tumors to neutron or photon radiation combined with cytokine therapyGilda G Hillman, Richard L Maughan, David J Grignon, et al.
Journal of Chemotherapy (Florence, Italy)|July 5, 2012
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myelomaMuneer H Abidi, Zartash Gul, Judith Abrams, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 16, 2012
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal functionMuneer H Abidi, Rishi Agarwal, Nishant Tageja, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 9, 2006
Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeletonAviva Levine Fridman, Lin Tang, Olga I Kulaeva, et al.
Translational Oncology|October 2, 2010
Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumorsGilda Gali Hillman, Vinita Singh-Gupta, Areen K Al-Bashir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2012
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trialMuneer H Abidi, Rishi Agarwal, Lois Ayash, et al.
Preventive Medicine Reports|July 14, 2023
The impact of high intensity interval training in a diverse group of cancer survivors: CAPABLE, a pilot studyJennifer L Beebe-Dimmer, David G Finlay, Julie J Ruterbusch, et al.
International Journal of Cancer|March 16, 2012
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNAMarie P Piechocki, Gen Sheng Wu, Richard F Jones, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 18, 2013
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaDivaya Bhutani, Jeffrey Zonder, Jason Valent, et al.
Neoplasia (New York, N.Y.)|September 3, 2009
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumorsGilda G Hillman, Vinita Singh-Gupta, Hao Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|July 23, 2003
Responsiveness of experimental prostate carcinoma bone tumors to neutron or photon radiation combined with cytokine therapyGilda G Hillman, Richard L Maughan, David J Grignon, et al.
Journal of Chemotherapy (Florence, Italy)|July 5, 2012
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myelomaMuneer H Abidi, Zartash Gul, Judith Abrams, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 16, 2012
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal functionMuneer H Abidi, Rishi Agarwal, Nishant Tageja, et al.
Pageof 8